Stockreport

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Limited American Depositary Shares  (TEVA) 
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm Check Earnings Report
US:NYSE Investor Relations: ir.tevapharm.com
PDF Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population [Read more]